AR040599A1 - Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad - Google Patents

Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad

Info

Publication number
AR040599A1
AR040599A1 AR20030102575A ARP030102575A AR040599A1 AR 040599 A1 AR040599 A1 AR 040599A1 AR 20030102575 A AR20030102575 A AR 20030102575A AR P030102575 A ARP030102575 A AR P030102575A AR 040599 A1 AR040599 A1 AR 040599A1
Authority
AR
Argentina
Prior art keywords
macular degeneration
patients
age
protection
related macular
Prior art date
Application number
AR20030102575A
Other languages
English (en)
Spanish (es)
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AR040599A1 publication Critical patent/AR040599A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AR20030102575A 2002-08-05 2003-07-17 Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad AR040599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40122002P 2002-08-05 2002-08-05

Publications (1)

Publication Number Publication Date
AR040599A1 true AR040599A1 (es) 2005-04-13

Family

ID=31495940

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102575A AR040599A1 (es) 2002-08-05 2003-07-17 Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad

Country Status (17)

Country Link
US (2) US20040127472A1 (https=)
EP (1) EP1539182A4 (https=)
JP (1) JP2005535691A (https=)
KR (1) KR20050026510A (https=)
CN (1) CN1674913A (https=)
AR (1) AR040599A1 (https=)
AU (1) AU2003281817A1 (https=)
BR (1) BR0313546A (https=)
CA (1) CA2494211A1 (https=)
DE (1) DE03742226T1 (https=)
ES (1) ES2244361T1 (https=)
MX (1) MXPA05000773A (https=)
PL (1) PL375024A1 (https=)
RU (1) RU2322239C2 (https=)
TW (1) TW200410699A (https=)
WO (1) WO2004012742A1 (https=)
ZA (1) ZA200500731B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127472A1 (en) * 2002-08-05 2004-07-01 Jerdan Janice A. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
MXPA05008396A (es) * 2003-02-20 2006-03-30 Alcon Inc Formulaciones de glucocorticoides para tratar angiogenesis ocular patologica.
AU2004249256A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of AMD with combination of ingredients
CA2539023A1 (en) * 2003-09-23 2005-04-14 Alcon Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US7257366B2 (en) * 2003-11-26 2007-08-14 Osmosis Llc System and method for teaching a new language
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
MX2009006146A (es) * 2006-12-18 2009-06-19 Alcon Res Ltd Dispositivos y metodos para la administracion de farmacos oftalmicos.
CN101759741B (zh) * 2008-11-06 2013-01-09 天津金耀集团有限公司 一种化合物及其在制备治疗血管新生的药物中的应用
CN101923856B (zh) 2009-06-12 2012-06-06 华为技术有限公司 语音识别训练处理、控制方法及装置
US20150037422A1 (en) * 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
RU2489146C1 (ru) * 2012-07-11 2013-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения "сухой" формы возрастной макулярной дегенерации

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
RU2051651C1 (ru) * 1988-07-07 1996-01-10 Институт химии поверхности АН Украины Основа для глазных капель
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
ATE283013T1 (de) * 1999-10-21 2004-12-15 Alcon Inc Medikamentenzuführvorrichtung
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US20040127472A1 (en) * 2002-08-05 2004-07-01 Jerdan Janice A. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis

Also Published As

Publication number Publication date
BR0313546A (pt) 2005-07-12
ZA200500731B (en) 2006-08-30
RU2005106234A (ru) 2005-08-10
KR20050026510A (ko) 2005-03-15
US20060166956A1 (en) 2006-07-27
AU2003281817A1 (en) 2004-02-23
MXPA05000773A (es) 2005-04-19
CN1674913A (zh) 2005-09-28
TW200410699A (en) 2004-07-01
WO2004012742A1 (en) 2004-02-12
US20040127472A1 (en) 2004-07-01
PL375024A1 (en) 2005-11-14
DE03742226T1 (de) 2006-03-09
ES2244361T1 (es) 2005-12-16
JP2005535691A (ja) 2005-11-24
CA2494211A1 (en) 2004-02-12
EP1539182A1 (en) 2005-06-15
EP1539182A4 (en) 2010-01-20
RU2322239C2 (ru) 2008-04-20

Similar Documents

Publication Publication Date Title
AR040599A1 (es) Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad
CU23980B1 (es) Formulación liposomal y proceso para la preparación del mismo
BRPI0608297A2 (pt) composições de lipossomos
IL181234A0 (en) Mixture of phytosterol ester(s) and 1,3-diglycerides(s) for use in the treatment of medical conditions
AU2003264282A1 (en) Phenethanolamine derivatives and their use in the treatment of respiratory diseases
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
WO2005027993A3 (en) Vascular access preservation in hemodialysis patients
AR040204A1 (es) Composicion de vacuna meningococica multivalente
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
JP2005535691A5 (https=)
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
WO2007128564A3 (en) Use of a compound with rankl activity
SI1781296T1 (sl) Kinazolinski derivati in njihova uporaba pri zdravljenju trombocitemije
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
AR027937A1 (es) Tratamiento de condiciones alergicas e inflamatorias
BRPI0407742A (pt) uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida
AR055939A1 (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso
BR0313230A (pt) Uso de carboxamidas para o tratamento de tinido
EP4523750A3 (en) Methods of reducing cerebrovascular events in patients with fabry disease
BRPI0411427A (pt) formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológica
AR059126A1 (es) Uso de sales de tiotropio en el tratamiento del asma persistente moderada
Lafleur et al. Cryptococcal cellulitis in a patient on prednisone monotherapy for myasthenia gravis

Legal Events

Date Code Title Description
FB Suspension of granting procedure